Startups 

We are building a world-leading proprietary functional genomics and data intelligence platform enabling accelerated drug target development, higher trial success rates in oncology, and meaningful label expansions. Our core platform technology is a novel disruptive “CRISPR” functional genomics gene editing approach called GENE SLICE, exclusive license from co-founder Zhneya Ivakine’s lab at the Sick kids hospital, Toronto Canada. 

Our lab is based in Amsterdam, and we have further support from experts working from remote locations in Copenhagen, Cambridge, and Toronto. We have 4 PhD level scientists in our lab in Amsterdam, one full time intern bioinformatician, one part time senior bioinformatician, and one full time senior software developer. And my-self, PhD and entrepreneur, taking care of sales and investments. Plus everything else. We have another 5 people supporting us on the side in fractional roles. One commercial advisor (future CCO), 3 co-founders; 1) Dx lead – MD PhD trained pathologist, 2) investor lead – senior VC investor 3) tech lead in Toronto, functional genomics and CRISPR Tx expert. Finally, we have recently started a board led by a former lawyer with +25 years of experience in M&A, licensing deals and investment in life science.  

We were incorporated in late 2022, first R&D contract with biopharma company in February 2023, and we started our lab in Amsterdam in December 2023 based on pre-seed funding from Innovatie Funds Noord Holland. We are now raising our 2M Euro Seed round to onboard scale the novel technology from co-founder’s lab and validating our scalable licensing partnership business model. We expect to close it in May 2026. In parallel, we have started raising our 25M Euro Series A round for scaling our first business model.